What is the recommended structured template for evaluating and managing patients with chronic kidney disease?

Structured CKD Evaluation and Management Template

The KDIGO 2024 guideline provides a comprehensive, algorithmic framework for CKD evaluation and management organized into five core domains: detection and staging, risk stratification, comprehensive treatment strategy, monitoring and medication management, and team-based care with referral criteria. 1

1. Detection and Staging Framework

Initial Assessment

• Test both eGFR and urine albumin (ACR) simultaneously in all at-risk patients—never rely on one measure alone 22
• Use creatinine-based eGFR (eGFRcr) as the initial screening tool (1B recommendation) 2
• Add cystatin C-based estimation (eGFRcr-cys) when creatinine-based estimates may be inaccurate or when clinical decisions hinge on precise GFR assessment (1C recommendation) 22

Confirming Chronicity

Do not assume CKD from a single abnormal result—this could represent acute kidney injury or acute kidney disease 22. Establish chronicity through:

• Prior GFR measurements spanning ≥3 months
• Historical albuminuria or proteinuria results
• Imaging showing reduced kidney size or cortical thinning
• Pathology demonstrating fibrosis/atrophy
• Medical history of conditions causing CKD
• Repeat measurements at and beyond 3 months 22

Clinical caveat: You may initiate CKD-specific treatments at first presentation if clinical context strongly suggests CKD, even before confirming 3-month chronicity 2

Establishing Etiology

Determine cause using a systematic approach 22:

• Clinical context and comorbidities
• Personal and family history
• Social and environmental exposures
• Complete medication review
• Physical examination findings
• Laboratory measures (consider disease-specific testing)
• Imaging studies
• Genetic testing when indicated
• Kidney biopsy when clinically appropriate to guide treatment decisions (2D recommendation) 22

2. Risk Stratification Algorithm

Kidney Failure Risk Prediction

Use externally validated risk equations to estimate absolute kidney failure risk (1A recommendation) 1. Apply specific thresholds to guide clinical decisions:

• 5-year risk of 3-5%: Triggers nephrology referral consideration alongside eGFR/ACR criteria 1
• 2-year risk >10%: Determines timing for multidisciplinary care initiation 1
• 2-year risk >40%: Mandates modality education, vascular access planning, and transplant referral 1

Important limitation: Risk equations developed for CKD G3-G5 are not valid for CKD G1-G2 1

Disease-specific tools: Use dedicated, externally validated equations for IgA nephropathy and autosomal dominant polycystic kidney disease 1

Cardiovascular Risk Assessment

• Use externally validated models developed within CKD populations or that incorporate eGFR and albuminuria to guide preventive therapies 1
• For mortality risk discussions regarding goals of care, apply CKD-specific all-cause mortality prediction models 1

3. Comprehensive Treatment Strategy

Core Treatment Framework

Treat with a comprehensive strategy targeting three interconnected domains 1:

Domain 1: CKD Pathophysiology

• Prevent and treat clinical symptoms and signs (including blood pressure control)
• Maximize health-related quality of life, physical function, work capacity, and socialization
• Monitor and treat laboratory abnormalities with health implications: anemia, CKD-mineral and bone disorders, potassium disorders, metabolic acidosis 1

Domain 2: CKD Outcomes

• Minimize progression to kidney failure
• Manage and reduce risk of complications: cardiovascular disease, hospitalization, gout, infections 1

Domain 3: Lifestyle Modification

Physical activity: Advise ≥150 minutes per week of moderate-intensity activity or to cardiovascular/physical tolerance level (1D recommendation) 1

• Tailor recommendations to age, ethnicity, comorbidities, and resource access
• Advise against sedentary behavior
• For high fall risk, specify intensity (low/moderate/vigorous) and type (aerobic vs. resistance)
• Consider weight loss advice for patients with obesity and CKD 1

Pediatric targets: ≥60 minutes daily physical activity per WHO guidelines 1

Referral strategy: Offer referrals to psychologists, renal dietitians/accredited nutrition providers, pharmacists, physical/occupational therapy, and smoking cessation programs where indicated 1

4. Monitoring and Medication Management

Imaging Studies

• Follow general population indications, weighing individual risks/benefits in CKD context 22
• Intra-arterial contrast: Assess AKI risk using validated tools before cardiac procedures 22
• Intravenous contrast: Manage per radiology society consensus in patients with AKI or eGFR <60 mL/min/1.73m² (CKD G3a-G5) 22
• Gadolinium (eGFR <30 mL/min/1.73m²): Preferentially use American College of Radiology group II and III agents 22

Medication Stewardship

• Establish collaborative relationships with pharmacists and use tools to enhance drug stewardship in complex medication regimens 22
• Educate patients to identify and report adverse events for proactive management 2

5. Specialist Referral and Team-Based Care

Adult Nephrology Referral Criteria

Refer to specialist kidney care services based on specific clinical triggers (refer to guideline Figure 48 for complete criteria) 22

Pediatric Nephrology Referral Criteria

Refer children and adolescents for 222:

• ACR ≥30 mg/g (3 mg/mmol) OR PCR ≥200 mg/g (20 mg/mmol) on repeat first morning void (when well, not menstruating)
• Persistent hematuria
• Any sustained eGFR decrease
• Hypertension
• Kidney outflow obstruction or urinary tract anomalies
• Known or suspected CKD
• Recurrent urinary tract infections

Symptom Assessment and Management

Systematically assess uremic symptoms (reduced appetite, nausea, fatigue/lethargy) at each consultation using standardized validated tools in patients with progressive CKD 222

Malnutrition screening: Screen CKD G4-G5 patients, those aged >65, pediatric patients with poor growth, or those with involuntary weight loss, frailty, or poor appetite twice annually using validated assessment tools 222

Nutritional intervention: Provide medical nutrition therapy under supervision of renal dietitians or accredited nutrition providers for patients with malnutrition 222

Multidisciplinary Team Structure

Enable access to patient-centered multidisciplinary care including 2222:

• Dietary counseling
• Medication management
• Education and counseling about KRT modalities
• Transplant options
• Dialysis access surgery
• Ethical, psychological, and social care

Patient education: Implement programs involving care partners to promote informed, activated patients 222

Technology integration: Consider telehealth (web-based, mobile applications, virtual visits, wearable devices) for education and care delivery 222

Adolescent Transition Planning

• Begin transition preparation at age 11-14 years using checklists to assess readiness 222
• Conduct part of each visit without parent/guardian present
• Provide comprehensive written transfer summary with oral handover to adult providers, including medical information and cognitive/social support details 222
• Transfer during periods of medical and social stability 2

---

This structured template operationalizes the KDIGO 2024 guideline into a practical workflow that moves systematically from detection through staging, risk stratification, comprehensive treatment, monitoring, and team-based care coordination, with specific thresholds and criteria at each decision point to guide clinical action 1222.